Overview

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.

Phase:

PHASE1

Details

Lead Sponsor:

AbbVie

Treatments:

risankizumab